{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T11:37:39Z","timestamp":1794829059137,"version":"4.9.1"},"reference-count":19,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,6,13]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>The addition of gemtuzumab ozogamicin to induction or maintenance therapy failed to improve the complete response rate or overall survival in patients with acute myeloid leukemia.<\/jats:p>","DOI":"10.1182\/blood-2013-01-466706","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T22:23:11Z","timestamp":1366150991000},"page":"4854-4860","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":583,"title":["A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia"],"prefix":"10.1182","volume":"121","author":[{"given":"Stephen H.","family":"Petersdorf","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Kopecky","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Southwest Oncology Group Statistical Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Slovak","sequence":"additional","affiliation":[{"name":"City of Hope Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Willman","sequence":"additional","affiliation":[{"name":"University of New Mexico, Albuquerque, NM;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nevill","sequence":"additional","affiliation":[{"name":"Vancouver General Hospital, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Brandwein","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry P.","family":"Erba","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Stiff","sequence":"additional","affiliation":[{"name":"Loyola University Medical Center, Maywood, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Stuart","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina, Charleston, SC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Stenke","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"14","key":"2019111817065827800_B1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia.","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111817065827800_B2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia.","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111817065827800_B3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century.","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"issue":"13","key":"2019111817065827800_B4","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/cncr.24373","article-title":"Outcomes and quality of care in acute myeloid leukemia over 40 years.","volume":"115","author":"Alibhai","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"2019111817065827800_B5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0145-2126(84)90001-8","article-title":"A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells.","volume":"8","author":"Griffin","year":"1984","journal-title":"Leuk Res"},{"issue":"4","key":"2019111817065827800_B6","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","article-title":"Expression of normal myeloid-associated antigens by acute leukemia cells.","volume":"67","author":"Dinndorf","year":"1986","journal-title":"Blood"},{"issue":"3","key":"2019111817065827800_B7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.1991.9.3.478","article-title":"A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.","volume":"9","author":"Scheinberg","year":"1991","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111817065827800_B8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00007890-199211000-00012","article-title":"The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.","volume":"54","author":"Appelbaum","year":"1992","journal-title":"Transplantation"},{"issue":"11","key":"2019111817065827800_B9","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"issue":"13","key":"2019111817065827800_B10","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111817065827800_B11","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"2019111817065827800_B12","author":"Deangelo"},{"issue":"24","key":"2019111817065827800_B13","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111817065827800_B14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111817065827800_B15","article-title":"Addition of gemtuzumab ozogamicin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study.","author":"Delauney","journal-title":"Blood"},{"issue":"9825","key":"2019111817065827800_B16","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"32","key":"2019111817065827800_B17","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111817065827800_B18","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"issue":"32","key":"2019111817065827800_B19","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2012.43.0132","article-title":"Gemtuzumab ozogamicin: time to resurrect? [Commentary]","volume":"30","author":"Ravandi","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/24\/4854\/1366152\/4854.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/24\/4854\/1366152\/4854.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T17:07:05Z","timestamp":1574096825000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/24\/4854\/31609\/A-phase-3-study-of-gemtuzumab-ozogamicin-during"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,13]]},"references-count":19,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2013,6,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2013-01-466706","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,13]]}}}